Takeda Pharmaceutical has submitted a new DPP-IV diabetes drug candidate — Alogliptin — in hopes the drug will replace its major earner Actos which loses patent protection in 2011.
Company news
January 3, 2008
5:00 am
Merck and Addex Pharmaceuticals entered a deal to develop a drug candidate for schizophrenia, under which Merck will pay Addex up to $702 million in cash plus royalties.
Sepracor in licensing pact for anti-epileptic compound
Sepracor has entered a licensing deal with Bial for the development and commercialization of Bial’s anti-epileptic compound BIA 2-093 in the US and Canada.
Wyeth sees generic threats, another delay on Viviant
Competitors have stepped up efforts to market generic versions of some of Wyeth’s biggest drugs, threatening to sap hundreds of millions of dollars in sales.
GlaxoSmithKline said approval of Cervarix will be delayed in the US after FDA regulators requested more information on the vaccine in a “complete response letter” to the drugmaker.
Novartis planning four new cancer drugs: Oncology president says
David Epstein, president of Novartis Oncology, said he hopes the drug maker will be able to start selling four new cancer treatments by the year 2011.
MM&M launches New Drug Dossier
November 30, 2007
5:00 am
MM&M’s New Drug Dossier is designed to give pharmaceutical marketers authoritative promotional and clinical insights on the latest new molecular entities in one online resource.
Amylin presents strong results for long-acting Byetta at R&D day
Positive results of a study involving Amylin’s long-acting release (LAR) version of Byetta (exenatide) were the highlight of the company’s R&D day in New York yesterday.
Newly discovered liver safety problems with high doses of Novartis’ diabetes treatment Galvus are expected to delay the European launch of the drug and have raised questions about whether the FDA will back its approval here in the US.